Novel compounds based on modified amino acids as inhibitors of SARS-CoV-2 replication, their formulations and applications

Abstract

This invention relates to novel compounds based on ethacrynic acid coupled with modified amino acids as illustrated in formula (I). These compounds are designed for the treatment of SARS-CoV-2, pathologies related to COVID-19, and diseases associated with β-coronaviruses. This invention also relates to their in vitro application for studying the inhibition of SARS-CoV-2 replication. Furthermore, this invention includes pharmaceutical compositions comprising, as an active ingredient, at least one compound of formula (I).